Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [31] Type 1 Diabetes Mellitus and Thromboembolism in Pregnancy
    Thomas, Jacob
    Brewerton, Charles
    Holmgren, Calla
    Harrison, Rachel
    [J]. AMERICAN JOURNAL OF PERINATOLOGY, 2025,
  • [32] A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
    Pollock, Richard F.
    Norrbacka, Kirsi
    Cameron, Chris
    Mancillas-Adame, Leonardo
    Jeddi, Mark
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (04) : 229 - 240
  • [33] Development and validation of a screening model for diabetes mellitus in patients with periodontitis in dental settings
    Su, Naichuan
    Teeuw, Wijnand J.
    Loos, Bruno G.
    Kosho, Madeline X. F.
    van der Heijden, Geert J. M. G.
    [J]. CLINICAL ORAL INVESTIGATIONS, 2020, 24 (11) : 4089 - 4100
  • [34] Type 1 Diabetes Mellitus
    Lee, Myung-Shik
    Kim, Kyoung -Ah
    [J]. JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2009, 52 (07): : 677 - 687
  • [35] Evaluation of Vascular Endothelial Function in Children with Type 1 Diabetes Mellitus
    Nocun-Wasilewska, Karolina
    Zwolinska, Danuta
    Zubkiewicz-Kucharska, Agnieszka
    Polak-Jonkisz, Dorota
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [36] The Diagnostic Utility of VibraTip for Distal Symmetrical Polyneuropathy in Type 2 Diabetes Mellitus
    Papanas, Nikolaos
    Pafili, Kalliopi
    Demetriou, Maria
    Papachristou, Stella
    Kyroglou, Soultana
    Papazoglou, Dimitrios
    Maltezos, Efstratios
    [J]. DIABETES THERAPY, 2020, 11 (01) : 341 - 346
  • [37] Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran
    Javanbakht, Mehdi
    Baradaran, Hamid R.
    Mashayekhi, Atefeh
    Haghdoost, Ali Akbar
    Khamseh, Mohammad E.
    Kharazmi, Erfan
    Sadeghi, Aboozar
    [J]. PLOS ONE, 2011, 6 (10):
  • [38] Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective
    Del Prato, Stefano
    Giorgino, Francesco
    Szafranski, Kirk
    Poon, Yeesha
    [J]. DIABETES OBESITY & METABOLISM, 2024, 26 (09) : 3633 - 3641
  • [39] Development and validation of a diabetic retinopathy risk prediction model for middle-aged patients with type 2 diabetes mellitus
    Wang, Gao-Xiang
    Hu, Xin-Yu
    Zhao, Heng-Xia
    Li, Hui-Lin
    Chu, Shu-Fang
    Liu, De-Liang
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [40] A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
    Henriksson, Martin
    Jindal, Ramandeep
    Sternhufvud, Catarina
    Bergenheim, Klas
    Sorstadius, Elisabeth
    Willis, Michael
    [J]. PHARMACOECONOMICS, 2016, 34 (06) : 569 - 585